Most physicians evaluating a GLP peptide program arrive at the conversation without a clear picture of what the underlying economics actually look like. What's missing is the cost structure: where the money comes from, where it goes, what the margins are on each compound, and how the financial model holds up at different candidate counts.
This article lays out the economics of a GLP peptide program in plain terms. The cost structure, the margin math, and some other variables that matter.
The cost structure: what you're actually buying
A starter package in a GLP program is fundamentally an inventory purchase with additional services attached. The practice buys a quantity of peptide, typically structured around a $30,000 initial order.
The three relevant cost categories are:
- Inventory cost: The wholesale cost of the peptide per unit (vial). This is the primary cost of goods. At Majestic published pricing: Semaglutide at $262.50 per 30mg vial, Tirzepatide at $750.00 per 200mg vial, Retatrutide at $525.00 per 60mg vial.
- Financing cost: If the practice uses PNC Healthcare financing for the starter order, the carrying cost is approximately $650/month over 60 months at 10% APR on a $30,000 draw. This is the baseline overhead the program must cover before it generates net revenue. To assist with this we offer you $700 worth of peptides every monnth for free.
- Program overhead: Staff time for candidate management, compliance documentation, storage, and administration. In established practices with efficient workflows, this is largely absorbed into existing overhead. In practices building the program from scratch, there may be a startup cost in staff time during the first 30–60 days.
The key insight on cost structure: Unlike most clinical services, the primary cost in a peptide program is inventory, a tangible asset with a shelf life, not a sunk cost. Inventory that moves quickly generates revenue. Inventory that doesn't move is capital tied up in product. The financial health of the program is therefore directly tied to candidate count and inventory velocity.
Gross margin by compound: not all peptides are equal
The three compounds have meaningfully different margin profiles, driven by their cost per mg and the volume of compound required per candidate per month. Understanding this matters for how a practice thinks about its compound mix.
| Compound | Cost/Vial | Vial Size | Cost/mg | Typical Candidate Volume/mo | Est. Cost/mo |
|---|---|---|---|---|---|
| Semaglutide | $262.50 | 30 mg | $8.75 | Lower mg/mo | Lower |
| Tirzepatide | $750.00 | 200 mg | $3.75 | Higher mg/mo | Moderate |
| Retatrutide | $525.00 | 60 mg | $8.75 | Moderate mg/mo | Higher |
Tirzepatide's $3.75/mg cost is the lowest of the three compounds despite its higher per-vial price — a consequence of its 200mg vial size. Practices that build a candidate base weighted toward Tirzepatide will find the cost-per-candidate-per-month economics favorable relative to the other compounds. This is worth understanding when evaluating compound mix, even though the clinical decision of which compound to use belongs entirely to the physician.
The inventory velocity question
The single most important variable in the financial model is how quickly the practice burns through its initial inventory. This is not just a function of candidate count, it's a function of candidate count multiplied by compound mix and average monthly usage per candidate.
A practice burning through a $30,000 inventory order in six months is cycling capital efficiently. Revenue exceeds the financing payment early, reorders build inventory depth, and the program develops momentum. A practice taking 18 months to move the same inventory has a different problem: outside the obvious slowing on the financial side, your inventory will start to expire if it takes your practice longer then 12 months to cycle through.
The inventory calculator on the Majestic program homepage runs this math in real time. Input your expected candidate mix and it returns your projected burn rate, the most honest single indicator of whether the program makes financial sense for your specific practice before you commit to anything.
Where the revenue actually comes from
It is worth being precise about the revenue model, because it is different from most clinical revenue streams physicians are accustomed to.
Insurance-billed services generate revenue through a coding and reimbursement structure that is largely outside the physician's direct control. The practice bills, the payer adjudicates, and the practice collects some fraction of what it billed, on a timeline that can stretch weeks or months.
A cash-pay GLP peptide program operates on a fundamentally different model. The practice purchases inventory at wholesale cost and provides it to candidates as part of a clinical program at a markup that reflects the value delivered. Revenue is collected at the point of service. There is no claims process, no adjudication, no 45-day collections cycle. The cash-pay structure is what makes the program's economics as clean as they are and it is also what makes the candidate volume variable so directly impactful on cash flow.
The compounding effect of retention: A candidate who continues their program for 12 months generates substantially more revenue than the initial month implies. The startup cost of acquiring and onboarding a candidate — intake, documentation, first visit — is a one-time cost. The monthly revenue from that candidate is recurring. Programs with strong candidate retention at months 3, 6, and 12 have dramatically better economics than programs with high early attrition, even at identical initial candidate volumes.
The financial case at different practice sizes
The economics look different depending on the size and type of practice. A few honest observations:
Small primary care or family medicine practices (under 500 active candidates)
The financial case is viable but depends heavily on identifying and converting the right subset of existing candidates. The program's economics can be tight at low candidates volumes. The Metis Profit Snapshot is particularly valuable here: knowing your specific candidate population's likely conversion rate before committing to the starter order is exactly the kind of information that gives you peace of mind about your decision.
Mid-size practices (500–2,000 active candidates)
This is where the program's economics are most straightforward. A practice with 1,000 active candidates likely has 80–150 individuals who meet a reasonable metabolic profile for a GLP program. Converting even 20–30 of those candidates in the first 90 days produces inventory velocity and revenue that comfortably exceeds the financing overhead. This is the base demographic for the program.
Weight loss clinics and metabolic medicine practices
For practices already focused on metabolic health, the program is effectively an inventory optimization play. The candidate base is already pre-selected. The question is cost of goods and supply chain reliability, not candidate conversion. These practices typically move inventory fastest and have the most mature financial picture from the program earliest.
Med spas and aesthetics practices
The cash-pay infrastructure is already built. Candidatess are already accustomed to paying out of pocket for clinical services. The marginal cost of adding a GLP program in terms of candidate education and billing infrastructure is low. The constraint is typically physician or NP oversight requirements depending on the state, not the economics themselves.
What the model does not account for
An honest financial overview has to name what the projections don't include:
- Candidate attrition: Some candidates discontinue within 90 days — cost intolerance, side effects, life circumstances. Programs that don't plan for attrition and build candidate pipelines accordingly will find their inventory burn rate slowing at the 3-month mark. Your complimentary Metis dashbaord helps alleviate some of this.
- Competition: The GLP market is competitive and getting more so. Practices that establish programs now benefit from first-mover advantage in their candidate population, but pricing pressure from direct-to-consumer telehealth platforms is a real market dynamic.
- Staff time in year one: The first 60–90 days of a new program require increased staff attention. Intake workflows, documentation templates, and candidate communication protocols that feel efficient by month four are not efficient on day one. While we assist in this, it is important to factor this in honestly.
The bottom line: The financial case for a well-run GLP peptide program at appropriate candidate volumes is sound. The economics are not complicated, they are a function of wholesale cost, inventory velocity, and candidate retention. The practices that perform best financially are those that approach the program with the same operational discipline they apply to any other revenue line: clear intake processes, consistent candidate follow-through, and a realistic picture of the candidate population before the first order is placed.
See the numbers for your specific practice.
The Majestic inventory calculator runs your compound mix and candidate volume against the actual cost structure, burn rate, monthly revenue projection, and financing coverage, before you commit to anything. Your Metis Profit Snapshot goes deeper: a personalized financial model built on your actual candidate population data.